千金药业发行股份购买资产过会

Core Viewpoint - The Shanghai Stock Exchange's M&A Review Committee approved Qianjin Pharmaceutical's asset acquisition plan, indicating compliance with restructuring conditions and information disclosure requirements [1] Group 1: Transaction Details - Qianjin Pharmaceutical plans to acquire a 28.92% stake in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and a 68% stake in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. [1] Group 2: Review Committee Requirements - The review committee requested the company to explain the basis and rationale for the projected gross margin levels of the main products during the forecast period, considering the impact of drug procurement and historical gross margin changes [1] - The committee also required the company to detail how the transaction will enhance product resource integration and the value of drug registration certificates, as well as the adequacy of information disclosure regarding the integration and management arrangements for the acquired companies [1]